Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is ...
Live from TTLC 2025: Mesothelioma and NUT Carcinoma
In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion of two of the most challenging thoracic malignancies – NUT carcinoma and mesothelioma. Listen to the episode to learn about the role of next-generation sequencing in diagnosis and treatment selection, as well as current and future targeted therapy in the management of both.
Guests
Melina Marmarelis, MD MSCE
Assistant Professor
Medical Director, UPenn Mesothelioma
University of Pennsylvania
Jia Luo, MD
Medical Oncologist, Thoracic Oncology Program, Dana-Farber Cancer Institute
Faculty, Brigham and Women's Hospital and Harvard Medical School
--------
44:47
LCC in Arabic: Chemo Immunotherapy in Metastatic NSCLC
Descriptions: As part of the IASLC's ongoing series of podcasts in world languages, Dr. Nagla Abdel Karim moderates a discussion in Arabic with Dr. Bashir Abu Aqeel and Dr. Fawzi Abu Rous. The group discusses chemoimmunotherapy in metastatic non-small cell lung cancer.
--------
15:09
Virtual Tumor Board: Treating EGFR NSCLC After TKI Resistance
In this episode of Lung Cancer Considered, host Dr. Stephen Liu moderates a Virtual Tumor Board case involving drug resistance in EGFR mutant NSCLC. This discussion takes the listener through the treatment of EGFR mutant NSCLC after acquired resistance to osimertinib.
Guest: Dr. Yasushi Goto from National Cancer Center, Japan in Tokyo
Guest: Dr. Rachel Sanborn, the Earle A. Chiles Research Institute of the Providence Cancer Institute in Portland, Oregon
--------
45:50
LAURA Study (Part 2) - Radiation Oncology Perspective
This episode of Lung Cancer Considered covers the recent FDA approval of Osimertinib after chemo-radiation in EGFR positive NSCLC based on the LAURA trial which was presented at the 2024 ASCO Annual Meeting. Host Dr. Narjust Florez goes in depth with podcast guest Dr. Pamela Samson about the LAURA Trial and its implications for patients and clinicians.
Guest: Dr. Pamela Samson is an assistant professor in the Department of Radiation Oncology at Washington University in St. Louis. Dr. Samson specializes in the care of thoracic malignancies and ways to deliver appropriate radiation therapy without compromising efficacy and diminishing toxicities.
--------
47:21
Lung Cancer in Mexico: Perspectives from the North and Ciudad de Mexico
En este episodio de Lung Cancer Considered, vamos a hablar sobre el cancer de pulmón en México. Tengo el placer de tener en este episodio dos doctores con mucha experiencia tratando y entendiendo las necesidades de los pacientes con cancer de pulmón en México. Este episodio es una introducción y esperamos tener conversaciones as profundas en el futuro.
Bio: Tenemos al Dr. Jorge Alatorre, Oncology clínico con Alta especialidad en Tumores del Tórax (Cáncer de pulmón y Mesotelioma). Y es jefe del Servicio de Oncología Médica del Instituto Nacional de Enfermedades Respiratorias (INER). También ofrece consulta en el Centro Médico ABC Santa Fe y en ONCARE ubicados en la Ciudad de México
Bio: Dr. Silviano Rios, Cirujano torácico de la ciudad de Monterrey en México. Atiende a sus pacientes en el Hospital Zambrano Hellion y TecSalud y se especializa en cirugía mínimamente invasiva.
Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.
Lung Cancer considered is funded in part by AstraZeneca, Daiichi Sankyo, Inc., and Takeda
Brasil